An official website of the United States government
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Trial Status: active
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and
tolerable when administered orally, alone or in combination with other anticancer agents,
to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Inclusion Criteria
Age ≥ 18 years.
Willing and able to give written informed consent.
Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor.
Documentation of KRAS mutation prior to the first dose of trial drug(s).
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Adequate cardiovascular, hematological, liver, and renal function.
Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).
Exclusion Criteria
Central nervous system (CNS) tumors or untreated or unstable metastases.
Inability to swallow oral medications.
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial. Other inclusion/exclusion criteria are specified in the protocol.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07458347.
Locations matching your search criteria
United States
Florida
Tampa
Moffitt Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Massachusetts General Hospital Cancer Center
Status: Active
Name Not Available
Pennsylvania
Philadelphia
Thomas Jefferson University Hospital
Status: Active
Name Not Available
Texas
Houston
UT MD Anderson Cancer Center
Status: Active
Name Not Available
Utah
Salt Lake City
Huntsman Cancer Institute/University of Utah
Status: Active
Name Not Available
This is a first-in-human, phase 1, open-label, multicenter clinical trial designed to
evaluate safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics and
preliminary activity of orally administered KST-6051 as monotherapy or in combination
with other anticancer agents. The trial seeks to enroll adults with advanced or
metastatic KRAS mutant solid tumors including but not limited to pancreatic ductal
adenocarcinoma, colorectal cancer, and non-small cell lung cancer whose cancers have
progressed after prior therapy or in whom standard therapy was not tolerated. The trial
includes a dose escalation phase in which higher doses of KST-6051 will be given in
subsequent groups of participants. The trial also includes a dose expansion phase to
further investigate KST-6051. Participants can stay in the trial as long as they benefit